

PCT/IL04/747.



מדינת ישראל
STATE OF ISRAEL

REC'D 13 SEP 2004	
WIPO	PCT

**Ministry of Justice
Patent Office**


משרד המשפטים
לשכת הפטנטים

This is to certify that annexed hereto is a true copy of the documents as originally deposited with the patent application particulars of which are specified on the first page of the annex.

זאת לתעודה כי
רצופים בזה העתקים
נכונים של המסמכים
שהופקדו לכתחילה
עם הבקשה לפטנט
לפי הפרטים הרשומים
בעמוד הראשון של
הנספח.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

This 30-08-2004 היום



Commissioner of Patents

נתאשר
Certified



לשימוש הלשכה
For Office Use

חוק הפטנטים התשכ"ז 1967-
PATENTS LAW, 5727-1967

ב ק ש ה ל פ ט נ ט
Application for Patent

מספר: Number	157535
תאריך: Date	21-08-2003
הוקדם/נדחה Ante/Post-dated	

אני, (שם המבקש, מענו - ולגבי גוף מאוגד - מקום התאגדותו)
I (Name and address of applicant, and, in case of a body corporate, place of incorporation)

Topimed Ltd.
South Industrial Zone
P.O.B. 7284
Ashkelon 78172
ISRAEL

טופימד בע"מ
אזור תעשייה דרום
ת.ד. 7284
אשקלון 78172

ששמה הוא:
Owner, by virtue of

בעל אמצאה מכח הדיון
of an invention, the title of which is:

תכשירים למניעת ניוון העור

(בעברית)
(Hebrew)


PREPARATIONS FOR THE PREVENTION OF SKIN ATROPHY

(באנגלית)
(English)

Inventor: Shabtay Dikstein

hereby apply for a patent to be granted to me in respect thereof.

המציא: שבטאי דיקשטיין
מבקש בזאת כי ינתן לי עליה פטנט.

* בקשת חלוקה - Application for Division	* בקשת פטנט מוסף Application for Patent of Addition	* דרישת דין קדימה Priority Claim		
* מבקשת פטנט from Application	* לבקשה / לפטנט To Patent/Appl.	מספר/סימן Number/Mark	תאריך Date	מדינת האיגוד Convention Country
No. _____ מס' Dated _____ מיום	No. _____ מס' Dated _____ מיום			
* יפוי כח: כללי/מיוחד - רצוף בזה / עוד יוגש P.O.A.: general / specific - attached / to be filed later - הוגש בענין _____ Has been filed in case _____				
המען למסירת הודעות ומסמכים בישראל Address for Service in Israel ריינהולד כהן ושותפיו עורכי פטנטים ת.ד. 34335 ירושלים 91342 טל. 02-6518880 פקס. 02-6523336				
חתימת המבקש Signature of Applicant		היום _____ שנת _____ 200 _____ This _____ of _____ 200		
		לשימוש הלשכה For Office Use		

טופס זה, כשהוא מוטבע בחותם לשכת הפטנטים ומושלם במספר ובתאריך ההגשה, הינו אישור להגשת הבקשה שפרטיה רשומים לעיל.
This form, impressed with the Seal of the Patent Office and indicating the number and date of filing, certifies the filing of the application, the particulars of which are set out above.

* מחק את המיותר Delete whatever is inapplicable

תכשירים למניעת ניוון העור

PREPARATIONS FOR THE PREVENTION OF SKIN ATROPHY

הוצאה לאור: 1978

FIELD OF THE INVENTION

The present invention relates generally to the field of topical preparations for skin treatment. More specifically, the present invention relates to topical preparations for treatment of skin aging and atrophy.

BACKGROUND OF THE INVENTION

When women enter into postmenopausal age, their estrogen as well as their androgen production drops significantly. Testosterone production in premenopausal women is about 250 micrograms per day whereas in postmenopausal women it is about 100 micrograms per day. In comparison to this, male testosterone production is about 7 milligrams per day. It is now recognized that postmenopausal women can have good benefits from both androgen and estrogen supplements. There are available on the market pills for postmenopausal women that contain orally active androgen methyltestosterone in addition to the usual estrogen.

It is known that androgens applied locally to the skin can have certain benefits. Estrogens are ineffective to the skin whereas corticosteroids accentuated degradative changes (Papa, C.M. J. Soc.: Cosm. Chem. 18, 549, 1967). However, the challenge has been to find an androgen derivative that is active locally but without any systemic influence. The absorption of testosterone through the skin is known (in fact, certain testosterone-delivering patches, worn on the skin, are available). Thus, it would be desirable to have an androgen-containing preparation effective for diminishing the results of aging on the skin but without producing any side effects due to absorption into the bloodstream.

Surprisingly, androgen-containing topical preparations that decrease atrophy of the skin due to aging or external factors, such as photoaging, or prolonged corticosteroid treatment have been found. Specifically, it has been found that locally applied testosterone esters (especially testosterone phenyl propionate), in which the ester portion contains more than 5 carbons, provided excellent local skin activity at relatively low concentrations of 0.1-1%. At such low concentrations, the absorption into the bloodstream is substantially negligible. The topical preparations of the present invention have been shown to ameliorate the degradative changes of senescence or of external

factors such as photodamage or corticosteroid atrophy, with negligible absorption into the blood.

It is noted that aging of the skin is mainly a problem of the dermis and by legal definition, a cosmetic product should not affect the dermis.

SUMMARY OF THE INVENTION

The present invention relates to topical skin preparations for the use in the prevention of atrophy and aging of the skin, comprising a testosterone ester including an esterifying acid having between six to eleven carbon atoms provided that the topical preparation has no estrogen or estrogen derivatives.

Examples of estrogen derivatives that should not be included in the preparation of the invention are estradiol or its esters, estriol or its esters and the like.

According to preferred embodiments of the present invention, the testosterone ester is testosterone phenyl propionate. Preferably, the testosterone phenyl propionate is in a concentration of 0.1-1% by weight of the total preparation.

Further according to preferred embodiments of the present invention, the skin preparations are the form of an oil solution. Preferably, the oil is a medium chain triglyceride.

Further according to preferred embodiments of the present invention the topical skin preparations may further include at least one additional therapeutically active agent, having no estrogenic activity. examples of such agents are oil soluble vitamins or their derivatives such as vitamin A or retinoic acid, Vitamin D₃ or calcitriol, vitamin E, essential fatty acids or their esters

The present invention also relates to a method for the treatment of atrophy or aging of the skin comprising administering to a patient in need of such treatment a topical skin preparation as described above.

DETAILED DESCRIPTION OF THE INVENTION

The following are meant to provide non-limiting examples for preferred embodiments of the topical skin preparations of the present invention.

Examples

Example 1: Oily Solution

Testosterone phenyl propionate 0.3% or 1% dissolved in medium chain triglycerides.

Suitable preservatives, antioxidants, and/or perfumes may also be added.

Example 2: Oily solution with vitamin E

The preparation of this solution was carried out as in Example 1 above with the addition of 2% vitamin E

Example 3: Oily solution with vitamin D

The preparation of this solution was carried out as in Example 1 above with the addition of 0.01% vitamin D₃.

Example 4: Oily solution with Vitamin A

The preparation of this solution was carried out as in Example 1 above with the addition of 0.25% vitamin A₁.

Example 5: Testosterone Phenyl Propionate In an oil rich in Essential Fatty Acids

Testosterone phenyl propionate 0.1 to 1% dissolved in safflower oil

Human Studies:

Eight postmenopausal women were treated with the skin preparation of Example 1 daily for three months on the skin of the inner arm. Biopsies were taken from the treated skin and from adjacent non-treated skin. The biopsies were evaluated and described according to the criteria described in Timar, F. et al. Skin Res. Technol. 6, 17, 2000). The results are given in Table 1 below.

TABLE 1

		Epidermal		Dermal	
Name		Thickness (microns)	Cell Layers	Interdigitation Index	Amount of GAG (%)
Changes from Control (data)					
TP	1	8.7 ± 1.5 (*)	0.18 ± 0.37	0.22 ± 0.07 (*)	2.7 ± 0.8 (*)
TP	0.3	0.3 ± 5.7	-0.2 ± 0.45	0.07 ± 0.04	2.2 ± 1.3

GAG= glucose amino glycan

TP= Testosterone phenyl propionate

* = significantly different from normal old cohort

CLAIMS

1. Topical skin preparations for the use in the prevention of atrophy and aging of the skin, comprising a testosterone ester with an esterifying acid having between six to eleven carbon atoms, provided that the topical preparation does not comprise estrogen or estrogen derivatives..
2. Topical skin preparations according to claim 1, wherein the testosterone ester is testosterone phenyl propionate.
3. Topical skin preparations according to claim 2, wherein the testosterone phenyl propionate is in a concentration of 0.1-1% by weight of the total preparation.
4. Topical skin preparations according to claim 3, in the form of an oil solution.
5. Topical skin preparations according to claim 4, wherein the oil is a medium chain triglyceride.
6. Topical skin preparations according to any one of claims 1-5, further comprising at least one additional therapeutically active agent. .
7. Topical skin preparations according to claim 6 wherein the additional therapeutic agent is selected from the group consisting of: vitamin A , retinoic acid, vitamin D₃, calcitriol,, vitamin E, essential fatty acid, essential fatty acid ester, or a combination of at least two of the above agents
8. A method for the treatment of atrophy or aging of the skin comprising administering to a patient in need of such treatment a topical skin preparation as described in any one of claims 1-7.

